| . | AOM 400 . | PP . |
|---|---|---|
| Randomized patients | n=148 | n=147 |
| All-patients-treated set | n=144 | n=137 |
| Full analysis set | n=136 | n=132 |
| Baseline demographicsa | ||
| Mean (SD) age, y | 42.6 (10.9) | 41.2 (10.7) |
| Mean (SD) age at schizophrenia onset, y | 28.5 (10.7) | 26.8 (9.5) |
| Mean (SD) schizophrenia duration, y | 14.1 (10.5) | 14.4 (10.7) |
| Male, n (%) | 86 (59.7) | 82 (59.9) |
| Baseline scale scoresb | ||
| QLS total score, possible range 0–126 (higher = better) | ||
| Mean (SD) | 66.0 (21.7) | 62.9 (21.5) |
| CGI-S score, possible range 1–7 (lower = better) | ||
| Mean (SD) | 4.0 (0.65) | 4.0 (0.65) |
| WoRQ total score, possible range 7–28 (lower = better) | ||
| Mean (SD) | 14.5 (3.45) | 15.3 (3.25) |
| SWN-S total score, possible range 20–120 (higher = better) | ||
| Mean (SD) | 83.6 (15.9) | 85.2 (14.6) |
| TooL total score, possible range 8–32 (lower = better) | ||
| Mean (SD) | 14.4 (4.4) | 14.3 (3.9) |
| . | AOM 400 . | PP . |
|---|---|---|
| Randomized patients | n=148 | n=147 |
| All-patients-treated set | n=144 | n=137 |
| Full analysis set | n=136 | n=132 |
| Baseline demographicsa | ||
| Mean (SD) age, y | 42.6 (10.9) | 41.2 (10.7) |
| Mean (SD) age at schizophrenia onset, y | 28.5 (10.7) | 26.8 (9.5) |
| Mean (SD) schizophrenia duration, y | 14.1 (10.5) | 14.4 (10.7) |
| Male, n (%) | 86 (59.7) | 82 (59.9) |
| Baseline scale scoresb | ||
| QLS total score, possible range 0–126 (higher = better) | ||
| Mean (SD) | 66.0 (21.7) | 62.9 (21.5) |
| CGI-S score, possible range 1–7 (lower = better) | ||
| Mean (SD) | 4.0 (0.65) | 4.0 (0.65) |
| WoRQ total score, possible range 7–28 (lower = better) | ||
| Mean (SD) | 14.5 (3.45) | 15.3 (3.25) |
| SWN-S total score, possible range 20–120 (higher = better) | ||
| Mean (SD) | 83.6 (15.9) | 85.2 (14.6) |
| TooL total score, possible range 8–32 (lower = better) | ||
| Mean (SD) | 14.4 (4.4) | 14.3 (3.9) |
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; CGI-S, Clinical Global Impression–Severity of Illness; QLS, Heinrichs-Carpenter Quality-of-Life Scale; PP, paliperidone palmitate once monthly; SWN-S, Subjective Well-Being Under Neuroleptics–short version; TooL, Tolerability and Quality of Life Questionnaire; WoRQ, The Work Readiness Questionnaire.
aBaseline and demographic data are from the all-patients-treated set.
bBaseline scale scores are from the full analysis set.
| . | AOM 400 . | PP . |
|---|---|---|
| Randomized patients | n=148 | n=147 |
| All-patients-treated set | n=144 | n=137 |
| Full analysis set | n=136 | n=132 |
| Baseline demographicsa | ||
| Mean (SD) age, y | 42.6 (10.9) | 41.2 (10.7) |
| Mean (SD) age at schizophrenia onset, y | 28.5 (10.7) | 26.8 (9.5) |
| Mean (SD) schizophrenia duration, y | 14.1 (10.5) | 14.4 (10.7) |
| Male, n (%) | 86 (59.7) | 82 (59.9) |
| Baseline scale scoresb | ||
| QLS total score, possible range 0–126 (higher = better) | ||
| Mean (SD) | 66.0 (21.7) | 62.9 (21.5) |
| CGI-S score, possible range 1–7 (lower = better) | ||
| Mean (SD) | 4.0 (0.65) | 4.0 (0.65) |
| WoRQ total score, possible range 7–28 (lower = better) | ||
| Mean (SD) | 14.5 (3.45) | 15.3 (3.25) |
| SWN-S total score, possible range 20–120 (higher = better) | ||
| Mean (SD) | 83.6 (15.9) | 85.2 (14.6) |
| TooL total score, possible range 8–32 (lower = better) | ||
| Mean (SD) | 14.4 (4.4) | 14.3 (3.9) |
| . | AOM 400 . | PP . |
|---|---|---|
| Randomized patients | n=148 | n=147 |
| All-patients-treated set | n=144 | n=137 |
| Full analysis set | n=136 | n=132 |
| Baseline demographicsa | ||
| Mean (SD) age, y | 42.6 (10.9) | 41.2 (10.7) |
| Mean (SD) age at schizophrenia onset, y | 28.5 (10.7) | 26.8 (9.5) |
| Mean (SD) schizophrenia duration, y | 14.1 (10.5) | 14.4 (10.7) |
| Male, n (%) | 86 (59.7) | 82 (59.9) |
| Baseline scale scoresb | ||
| QLS total score, possible range 0–126 (higher = better) | ||
| Mean (SD) | 66.0 (21.7) | 62.9 (21.5) |
| CGI-S score, possible range 1–7 (lower = better) | ||
| Mean (SD) | 4.0 (0.65) | 4.0 (0.65) |
| WoRQ total score, possible range 7–28 (lower = better) | ||
| Mean (SD) | 14.5 (3.45) | 15.3 (3.25) |
| SWN-S total score, possible range 20–120 (higher = better) | ||
| Mean (SD) | 83.6 (15.9) | 85.2 (14.6) |
| TooL total score, possible range 8–32 (lower = better) | ||
| Mean (SD) | 14.4 (4.4) | 14.3 (3.9) |
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; CGI-S, Clinical Global Impression–Severity of Illness; QLS, Heinrichs-Carpenter Quality-of-Life Scale; PP, paliperidone palmitate once monthly; SWN-S, Subjective Well-Being Under Neuroleptics–short version; TooL, Tolerability and Quality of Life Questionnaire; WoRQ, The Work Readiness Questionnaire.
aBaseline and demographic data are from the all-patients-treated set.
bBaseline scale scores are from the full analysis set.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
